Xolair vs Daliresp
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Xolair | US Daliresp | |
|---|---|---|
| Generic name | omalizumab | roflumilast |
| Drug class | Anti-IgE Monoclonal Antibody | PDE4 Inhibitor (Oral) |
| Treats | Allergic asthma, chronic hives, food allergy | Chronic obstructive pulmonary disease (COPD) |
| Category | Respiratory | Respiratory |
| Manufacturer | Genentech/Novartis | AstraZeneca |
| Year approved | 2003 | 2011 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $95M | — |
| Common side effects | Anaphylaxis (severe allergic reaction), Injection site reactions, Joint pain, Headache | Diarrhea, Weight loss, Nausea, Headache |
Frequently asked questions
Is Xolair or Daliresp better?
Neither is universally "better." Xolair (omalizumab) and Daliresp (roflumilast) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xolair and Daliresp?
Xolair is a Anti-IgE Monoclonal Antibody made by Genentech/Novartis, while Daliresp is a PDE4 Inhibitor (Oral) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xolair has the larger estimated TV advertising budget of the two.